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INTRODUCTION 
 
 
 INTRODUCTION 
 
Vulvar problems account for a significant number of patients attending 
gynecological clinics. Vulvar diseases can affect any age group. Too commonly the 
vulvar disorders are missed and any changes in the  normal anatomy are not 
recognized. Many women do not seek medical advice due to embarrassment and 
social factors. 
 Vulvar carcinoma continues to rise in incidence in recent years. Therefore 
attempts to reduce this cancer must focus on identifying precursor conditions like 
vulval intraepithelial neoplasia, lichen sclerosus and other dystrophies which could 
progress to malignancy if left untreated. 
 The scope of this study is to evaluate the various vulvar diseases encountered 
among the symptomatic patients attending the gynecological OPD at our institute, a 
tertiary care center. 
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AIM OF THE STUDY 
 
1. To evaluate the vulvar diseases among the symptomatic patients attending 
gynecological outpatient department at the Institute of Obstetrics and 
Gynaecology, Chennai. 
 
2. To study the epidemiology of the various vulvar diseases including the socio-
demographic factors, age distribution, clinical features and histo-pathological 
features among the women included in the study.  
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MATERIALS AND METHODS 
 
NATURE OF THE STUDY: 
 This study is an observational clinical study conducted on symptomatic 
women attending gynecological clinics at the Institute of Obstetrics and Gynaecology, 
Chennai. 
 Women who are 30 years of age and above and who presented with 
symptoms related to vulvar diseases like pruritus, pain, mass or ulcers in the vulva are 
the subjects of this study. 89 cases who fulfilled the above criteria and who consented 
to participate in this study are the subjects included. 
STUDY PERIOD: 
The study period is from May 2010 to April 2011 (one year period). 
STUDY SETTING: 
The Institute of Obstetrics and Gynaecology, Chennai. 
ETHICAL CLEARANCE: 
Ethical committee clearance obtained 
CONSENT: 
An informed consent obtained from all patients participating in the study. 
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SUBJECTS: 
INCLUSION CRITERIA: 
¾ Women of age 30 years and above. 
¾  Patients with complaints of pruritus vulva. 
¾  Patients with pain in the vulval region. 
¾  Patients with mass or ulcer in the vulva. 
 EXCLUSION CRITERIA: 
¾ Women under the age of 30 years. 
¾  Pregnant women. 
SAMPLE SIZE   :   89 cases. 
 SAMPLING TECHNIQUE :    Purposive sampling 
COLLABORATING UNITS: 
¾ Dept of Pathology,IOG 
¾ Dept of Medical Oncology,IOG  
¾ STI clinic,IOG 
¾ Colposcopy clinic,IOG 
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METHODOLOGY 
 
 
Good management begins with a tailored history. Hence all the participants in 
the study are interviewed using a well- structured proforma. After getting an informed 
consent regarding their willingness to participate in the study, a detailed history is 
obtained including vital information on socio-demographic details, educational status, 
menstrual, marital, obstetric history, relevant past history, family and personal history 
including sexual history. 
 The patients are subjected to examination including general, systemic and 
local examination of the vulva. With the patient in dorsal position the external 
genitalia is examined for any abnormalities in colour, shape or texture of the vulvar 
region. A speculum examination done using Sim’s metallic speculum and any 
associated cervical or vaginal lesions noted. Papanicolaou smear taken using a 
wooden Ayre’s spatula with a 360 degree sweep at the squamo- columnar junction of 
the cervix. The material so obtained is spread on a glass slide before it is air-dried and 
fixed with 95% ethanol and later stained. Potassium hydroxide smears using scrapings 
from the vulvar skin in all patients with symptoms of pruritus with associated white 
discharge. The smears were subjected to microscopic examination. 
 Careful bimanual examination and a per-rectal examination done in all 
patients to rule out any associated pelvic pathology. Blood sugar tests done in all 
patients to rule out diabetes. 
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COLPOSCOPY OF VULVA (VULVOSCOPY) 
 A colposcope is a low-power binocular microscope with a focal length of 
approximately 20-30 cm with a co-axial light source focus for optimal vision. 
Developed in 1925, it is now well used in clinical practice for defining and 
delineating abnormal lesions of the cervix and also the vulva.  
With the patient in dorsal position a Cusco’s self retaining metallic speculum 
is introduced. The cervix and vagina visualized for evidence of any abnormalities like 
growth after applying 3% acetic acid for 3 minutes followed by Lugol’s iodine. 
Biopsy taken from any aceto-white iodine-negative suspicious areas. Vulvoscopy then 
performed by swabbing the whole vulva liberally with 3% acetic acid for 5 minutes. 
The vulva is systematically examined from the introitus outwards to labia minora, 
majora, perineum, peri-anal region and finally the clitoris. Any abnormal aceto- white 
areas, changes in surface contour or angioarchitecture are noted for biopsy. 
VULVAL BIOPSY: 
 The most important method of evaluating vulvar lesions is the histo-
pathological examination of the biopsy specimen.Abnormal aceto-white areas, mosaic 
pattern, punctuations, raised surface contour are ideal sites for biopsy. Approximately 
10 minutes before biopsy about 10 ml of 1% lignocaine solution is infiltrated for local 
anaesthesia. The skin is prepared with povidone-iodine solution. The skin at the 
biopsy site is elevated with Allis forceps and a scalpel is used to sever the base of the 
skin and a disc- shaped sample of skin is obtained, sent in a labeled formalin 
containing container. The skin edges are sutured with 1-0 catgut. 
 The histo-pathological reports are analysed. High risk patients are identified 
and treated and motivated for regular follow-up by creating awareness regarding 
cancer screening.                                 
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REVIEW OF LITERATURE 
The study of vulvar diseases has become important over the last few decades. 
The vulva is the part of the female external genital tract located between the genitor-
crural folds laterally, mons pubis anteriorly and the anus posteriorly. 
 It is composed of the vestibule, the clitoris, labia minora , labia majora and 
the mons pubis.  Embryological uniqueness of the vulva is that it arises from all the 3 
germ layers namely the urogenital ectoderm, the paramesonephric mesoderm and the 
cloacal endoderm. The epithelium is highly variable ranging from non-keratinized 
squamous epithelium to the keratinized epithelium associated with hair follicles and 
apocrine glands. 
 VULVAL INFECTIONS: 
Although the stratified squamous epithelium and the acidic secretions of the 
apocrine glands provide an effective defense mechanisms, infections can affect the 
vulvar skin or structures in the vulva like Bartholin’s, sebaceous, sweat glands. 
 VULVAL CANDIDIASIS: 
Vulvovaginal candidiasis (VVC) is an extremely common infection in women 
of childbearing age of all strata of society. It is estimated that about 75% of women 
will experience this infection at least once during their life time. Over 85% of cases 
are caused by Candida albicans, while Candida tropicalis and glabrata are more 
common in diabetic women. Often seen in patients with altered immune system like 
HIV infection, uncontrolled diabetes, steroids and frequent antibiotic therapy. 
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 Patients present with intense pruritus associated with curdy white discharge 
p/v. The vulva is erythematous or may show white adherent film or  discolouration. 
Potassium hydroxide smears show the presence of pseudohyphae.  Treatment  is oral 
or topical antifungals. 
 Sobel JD et al reported that it has now been excluded from the ranks of 
sexually transmitted diseases and is also not a notifiable disease. In 15% of these 
cases the mycotic infection may evolve in a “cyclic recurrent type” (RVC) defined as 
four or more episodes of mycotic vulvovaginitis during one year18. 
 An epidemiological study of vulvovaginal candidiasis in women of 
childbearing age conducted in India in 2007 N.Jindal et al reported out of 350 women 
of 16-45 years of age, with the complaints of vaginal discharge and/or vaginal itching 
positive culture for Candida species was obtained in 82 (23.4%) women. Of these, 61 
(74.4%) were Candida albicans and 21 (25.6%) were non C . albicans. There was a 
consistent increase in the incidence of VVC from second to fourth decade of life 
followed by a decline. This could be because of the influence of sexual activity. The 
study showed that women of low socioeconomic status, unsatisfactory genital hygiene 
and those who were using tight, poorly ventilated, nylon underclothing showed 
significantly higher incidence of VVC than those of middle class19. 
CONDYLOMA ACUMINATUM/ VULVAL WARTS: 
 It is a cutaneous benign neoplasm caused by Human Papilloma virus types 6, 
11. It typically has a verrucous, papillary or sessile appearance and exhibits viral HPV 
cytopathological effects. It is widespread in immunocompromised patients. 
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 In a study on a correlative analysis of cervical lesions in patients with vulva 
condyloma acuminatum Qing Li et al reported that out of 418 cases of vulval 
condylomata studied from May 2002 to April 2004 high-risk HPV (+) infections were 
detected in 68.7% (287/418) of the cases. Among those patients, 20.6% (59/287) had 
concurrent subclinical cervical intraepithelial neoplastic (CIN) lesions. Among the 
high-risk HPV(−) 31.3% (131), patients 7.6% (10/131) had concurrent subclinical 
CIN lesions 21 .The patients are at high-risk for CIN and cervical cancer. We must pay 
more attention to the cervix in cases with vulva condyloma acuminatum. 
 Clinical examination is sufficient to diagnose most external genital warts 
Biopsy is seldom necessary to accurately diagnose visible genital warts. Detection and 
typing of HPV are not currently recommended for diagnosis or management of 
external genital warts. 
Scissors or scalpel excision is best mode of treatment when a tissue specimen 
to be submitted for histopathological examination is needed to rule out malignancy. 
 A.Ferenczy reported the therapeutic effectiveness of the carbon dioxide laser 
was evaluated in 55 women with condylomata acuminata of the vulva but also of the 
urethral meatus and anal region and in 11 women with multicentric vulvar 
intraepidermal neoplasia. The rates of persistence and recurrence were only 13% and 
5% respectively for condylomata and were both 9% for intraepidermal neoplasia22. 
 Other rare infections which may affect the vulva includes VULVITIS due to  
sexually transmitted infections  like Gonorrhoea, Syphilis, 
Chancroid,Lymphogranuloma Venereum, Granuloma inguinale and viral infections 
like Herpes genitalis, Herpes zoster, Molluscum contagiosum and rarely due to 
parasitic infestations like Pediculosis, Scabies. 
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INFLAMMATORY VULVAL DYSTROPHIES: 
LICHEN SCLEROSUS: 
 In 1887, Hallopean first described lichen sclerosus and used the term lichen 
plan sclereus. The exact etiology is still unknown. It is associated with other 
autoimmune disorders like vitiligo, thyroiditis, and alopecia. Histologically, it is 
characterized by hyperkeratosis, thinning of dermis. There is mounting evidence to 
suggest that autoimmune mechanisms are involved in its pathogenesis. 
 LS in females has two peak ages of presentation. The first of these occurs in 
prepubertal girls and may resolve or continue beyond the menarche. The other peak of 
incidence is in postmenopausal women although this suggests a hormonal influence. 
 In a clinical study of 26 cases of lichen sclerosus by Singh et al  between 
2005-2007, the mean age was 44 years and the median duration  2.5 years ( 2 weeks 
to 40 years)1.  
There is a 4-5% risk of developing squamous cell carcinoma in patients with 
lichen sclerosus. However, histopathological examination of vulvar SCCs indicates 
that about 60% occur on a background of LS. A clinical study of anogenital SCC 
presenting to a vulvar clinic demonstrated that 14 of 23 cases occurred on a 
background of LS23. 
 Topical corticosteroids are considered the treatment of choice for this 
condition. Recently, nonsteroidal immunomodulatory topical calcineurin inhibitors 
(TCIs) have been increasingly used in the management of genital LS according to 
Meffert JJ Davis et al16. 
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 Patients treated with topical steroids 0.05% clobetasol propionate. In a series 
of 81 women Lorenz and coworkers reported 77% complete remission after treatment 
with topical steroids. 
 In a study on LS,  Cooper et al found out of  a  total of 327 women and girls 
with the typical clinical features of LS four women developed vulvar intraepithelial 
neoplasia alone, 6 developed squamous cell carcinomas (SCCs) alone, and 1 
developed an SCC on a grade 3 vulvar intraepithelial neoplasia. The mean age at 
diagnosis of the SCCs was 63.8 years (range, 39-82 years) and the mean duration of 
vulvar symptoms before diagnosis of an SCC was 30.8 years (range, 0-44 years)24. 
 In a study on Non-neoplastic disorders of the vulva in 2008, Andrew. T. 
Goldstein et al found  that the increased risk of developing squamous cell carcinoma 
is approximately 5 percent in patients with lichen sclerosus25. Patients with lichen 
sclerosus are also at a higher risk for autoimmune disorders and should be screened 
appropriately. 
LICHEN SIMPLEX CHRONICUS: 
 It is the end stage of chronic itch-scratch-itch cycle. Intense chronic pruritus 
results in repetitive scratching and thickening of skin called LICHENIFICATION. It 
may co-exist with other chronic dermatosis like lichen sclerosus. Also known as 
neurodermatitis, pruritus vulvae, squamous hyperplasia, and hyperplastic dystrophy. 
The etiology of the initiating pruritus that leads to LSC includes numerous irritative 
and infectious disorders including candidiasis, atopic dermatitis, contact dermatitis, 
and eczema. 
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 Biopsy shows prominent acanthosis with deepening of rete pegs with 
hyperkeratosis without atypia. Treatment includes breaking the itch-scratch-itch cycle 
by antihistaminics and topical steroids. 
In a study on pattern of non-venereal dermatosis of female genital tract in 
South India by Singh et al in 2008 out of 120 patients in the study 16  had lichen 
simplex  chronicus (13.3%) with a mean age of 49.9 years and a median duration of 2 
years of itching2.  
LICHEN PLANUS: 
 Lichen planus is a heterogenous condition affecting the skin and mucous 
membranes anywhere in the body. Erosive LP which affects mucous membranes of 
vulva and vagina whereas cutaneous LP has a classical violaceous flat-topped papules 
on the trunk and non-mucosal areas of genitalia. Etiology is unknown however 
autoimmunity plays a role in pathogenesis. LP affects approximately 1% of all 
women, most commonly on the oral mucosa. Approximately 25% of women with oral 
LP also have vulvovaginal involvement the peak incidence ranges from ages 30 to 60 
years. The true incidence of LP is difficult to assess. 
 Advanced stages of disease produce scarring, adhesions and introital 
narrowing. Biopsy shows band-like lymphocytic infiltration at the dermo-epidermal 
junction with saw-toothed rete ridges. 
 Kingston et al recommended topical steroids as first line. Surgery for scarring 
and reversal of sexual function is needed for young women. Like lichen sclerosus, 
non-healing erosive LP can progress to squamous cell carcinoma4. 
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 Kennedy et al a retrospective study of 113 women with erosive  vulvar LP 
only one case developed subsequent vulvar cancer however estimating the risk was 
difficult due to low prevalence of the disease. The mean age at presentation for 
women with lichen planus was 50 years. The potential for malignant transformation in 
vulvovaginal LP is not well known. Oral LP is clearly associated with increased risk 
of squamous cell carcinoma and several case reports have suggested that the same 
association holds true for vulvovaginal LP17. 
 In a series of 61 patients with vulvar carcinoma by Andrew. T. Goldstein,      
3 were found to have the histologically confirmed LP adjacent to the vulvar tumor. 
Current recommendations encourage regular vulvovaginal examinations in patients 
with lichen planus and biopsy of any suspicious lesions26. 
BENIGN CYSTS OF VULVA 
BARTHOLIN’S CYST: 
 These are the most common cystic growths in the vulva. 2% of women 
develop this condition at sometime in life more common in the reproductive age 
group. It carries low risk of bartholin gland carcinoma 0.114 Ca per 100000 women 
years9. Excision biopsy is needed only for postmenopausal women to rule out 
adenocarcinoma. Treatment of cyst includes marsupialization/incision and drainage. 
Bartholin gland abscess is 3 times more common than cysts. They are polymicrobial 
in origin and hence treated with incision and drainage under broad spectrum antibiotic 
coverage. Recurrence occurs in 10-15% of cases30. 
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Bartholin’s abscess I & D done 
LIPOMA: 
 Lipoma is a benign tumor occurring in the vulva that is composed of 
primarily fat cells (adipocytes). Can occur in all age groups. It presents as a soft well-
defined mass with normal overlying skin. Histology composed of mature fat cells 
with strands of fibrovascular tissue. Treated with excision in symptomatic patients. 
MUCOUS CYSTS OF VULVA: 
 These are benign cystic dilatation of minor vestibular glands in the introitus 
lined by mucous secreting columnar epithelium and contains typical mucoid 
material.Treatment is excision. 
LEIOMYOMA OF VULVA: 
 It is a rare smooth muscle tumor arising from the smooth muscles of blood 
vessels,erectile tissue, skin and from the smooth muscles of the erector pili. Patient 
presents as a mobile firm to soft mass. Histology composed of spindle-shaped smooth 
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muscle cells arranged in interlacing bundles. Treatment is surgical excision to rule out 
malignancy.  
OTHER RARE BENIGN CYSTIC OR SOLID VULVAR LESIONS 
include hemangioma, acrochordon, hidradenoma, Skene duct cysts, vulvar hematoma, 
fibroma. 
 VIN (VULVAR INTRAEPITHELIAL NEOPLASIA): 
 VIN is a proliferative intraepithelial squamous process associated with HPV 
infection, characterized by abnormal epithelial maturation, nuclear enlargement and 
nuclear atypia. It is categorized into VIN I (mild dysplasia), VIN II (moderate 
dysplasia) and VIN III (severe dysplasia).The term VIN has replaced the terms 
Bowen’s disease, Erythroplasia of Queyret, Bowenoid papulosis. 
 The BETHESDA system terminology “low grade” and “high grade”is applied 
to VIN I and VIN II/VIN III respectively. But as per the latest ISSVD classification in 
2004 the term VIN I is thought to be secondary to HPV infection and they combined 
VIN II &VIN III as simply VIN. 
 Histologically, there are two types of VIN namely, CLASSICAL VIN 
(basaloid and warty subtypes) and UNDIFFERENTIATED VIN (simplex). Classical 
VIN is multifocal, multicentric, HPV related, occurring in young women whereas, the 
poorly differentiated form of VIN are unifocal, unrelated to HPV and are linked to 
chronic itch-scratch-itch cycle associated with squamous cell hyperplasia, lichen 
sclerosus, lichen simplex chronicus. 
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 Basta et al in a study of 293 women of VIN aged between 23-76 years an 
increased frequency of VIN in young women has been observed for the past 15 years. 
In a group <45 years of age, those lesions were multifocal in 43 cases (63.2%) and 
unifocal in 25 patients (36.8%).And in the group of >45 years multifocal in 35 cases 
(31.8%) and unifocal in 75 cases (68.2%) 15. 
 JONES et al in a study of 405 cases of VIN II-III between 1962-2003 
reported a progression to malignancy occurred in 10 out of 16 untreated cases with a 
mean duration of 3.9 years. Spontaneous regression occurred in 47 cases (11.6%) with 
a median duration of 9.5 months. He also reported a decrease in mean age from 50 in 
1980  to 39 in 2003 due to increased HPV prevalence28. The classical forms best 
treated by excision or ablation and the simplex forms respond well to topical steroids.  
The development of undifferentiated VIN and vulvar SCC mirrors that of 
cervical intraepithelial neoplasia (CIN) and cervical SCC, the latter caused by high-
risk human papilloma virus in nearly 100% of the cases. Multicentric HPV infections 
affecting vulva, cervix, vagina and anus simultaneously have been described making a 
thorough examination of the entire lower female anogenital tract obligatory. 
VULVAR CANCER: 
 Vulvar cancer accounts for about 3 - 5 % of cancers of the female genital tract 
and 0.6% of all cancers in women. In the United States, women have a 1 in 406 
chance of developing vulvar cancer at some point during their life. The American 
Cancer Society's most recent estimates for vulvar cancer in the United States are for 
201127: 
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¾ About 4,340 cancers of the vulva will be diagnosed 
¾ About 940 women will die of this cancer27. 
The majority of vulvar carcinomas are squamous cell ca carcinomas (90%) 
followed by melanomas, adenocarcinomas, basal cell carcinomas and sarcomas. 
Verrucous carcinoma, a subtype of invasive squamous cell vulvar cancer, appears as 
cauliflower-like growths similar to genital warts. According to  WHO/ICO 
Information Centre on HPV and Cervical Cancer (HPV Information Centre) and 
Human Papillomavirus and Related Cancers in India September 2010 Updates, 
worldwide, about 60% of all vulvar cancer cases occur in developed countries, 
indicating the limited impact of cervical screening programmes to prevent vulvar and 
vaginal cancers. Vulvar cancer is common in older women with approximately 66% 
of cases diagnosed at or above 70 years.  
Incidence of vulvar cancer by cancer registry in India 
Cancer registry Period N cases Crude rate ASR 
Chennai 1998-2002 53 0.5 0.6 
Karunagappally 1998-2002 1 0.1 0.1 
Mumbai 1998-2002 65 0.2 0.3 
Nagpur 1998-2002 28 0.6 0.7 
New Delhi 1998-2002 82 0.3 0.5 
Poona 1998-2002 8   0.1          0.1 
Trivandrum 1998-2002 10   0.3          0.3 
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(ASR: Age-standardized rate. Standardized rates have been estimated using the direct 
method and the World population as the reference. 
1. Accumulated number of cases during the period 
2. Rates per 100,000 women per year) 
Regarding studies on HPV prevalence among cases of vulvar cancer in India 
no data available yet.  
A study on review of 56 patients younger than 45 years who were diagnosed 
with vulvar squamous cell carcinoma between 1994 and 2006 found that median age 
was 38 years. Of patients with advanced disease, 53.3% were smokers, 40% had 
human papillomavirus (HPV) exposure, 46.7% had a history of vulvar intraepithelial 
neoplasia (VIN) and 6.7% were immunocompromised. Symptoms were present for 
more than 12 months in 47%, but symptom duration did not correlate with stage (P = 
.42) or positive lymph nodes (P = .28). Young women with vulvar cancer tend to have 
early-stage disease, smoke, have a history of HPV and have VIN28. 
 The epidemiological pattern of cancer vulva is changing over the past 2 
decades. JUDSON et al reviewed 13,176 in situ and invasive vulvar carcinomas from 
the Surveillance, Epidemiology and End-Results (SEER) program database over a 28-
year period (1973-2000); 57% of cases were in situ. There was a 411% increase in the 
incidence of in situ carcinomas during 1973-2000 until the age of 40-49 years due to 
changing sexual behavior, smoking, HPV infection while the incidence of invasive 
cancer increased 20% during the same period especially after the age of 50 years29.  
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ETIOLOGY: 
 No specific etiological factor has been identified for vulvar cancer. 
Epidemiological evidence to date suggests that there are two different etiologic paths 
at work in vulvar carcinogenesis. 
¾ The keratinizing type is seen in women older than 50 years of age, 
associated with non-neoplastic epithelial disorders like chronic 
inflammation or lichen sclerosus. They tend to be unifocal and not 
HPV related. 
¾ The basaloid or warty type is often seen in women under the age of 50 
years and is associated with HPV infection, VIN and smoking. 
RISK FACTOR ANALYSIS: 
 The epidemiological risk factors for cancer vulva are similar to those of 
cervical cancer like HPV infection, condylomata, higher no. of sexual partners, 
smoking, tobacco use, sexually transmitted diseases, immunosuppression, VIN and 
other vulval dermatoses like lichen sclerosus. The risk of vulvar cancer goes up as 
women age. Less than 20% of cases are in women younger than age 50, and more 
than half occur in women over age 70. The average age of women diagnosed with 
invasive vulvar cancer is 70 years.  
Two types of HPV, HPV 6 and HPV 11, cause most cases of genital warts. 
These 2 types are seldom linked to cancer, and so are called low-risk types of HPV. 
However, other HPV types have been linked with oral, anal, and genital cancers and 
are known as high-risk types of HPV. These include HPV 16, HPV 18, HPV 31 as 
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well as others. Infection with a high-risk HPV may produce no visible signs until pre-
cancerous changes or cancer develops.  
About half of all vulvar cancers are linked to infection with the high-risk HPV 
types. HPV linked vulvar cancer is more common in younger women and is seen less 
often in older women.  
In a case series HPV DNA prevalence ranged from 72-100% among cases of 
high grade vulvar neoplasias (VIN III) and 27.3-100% among vulvar cancers(3.9-
6.3% in keratinizing types). Similarly metaanalysis estimated a HPV prevalence of 
76% for VIN and 36% for vulvar carcinomas.HPV 16 was the most common type 
detected (65-93% in VIN and 71% of vulvar cancers) followed by HPV18. 
  Smoking increases the risk of developing vulvar cancer. Among women who 
have a history of HPV infection, smoking further increases the risk of developing 
vulvar cancer.  
HIV virus damages the body's immune system; it makes women more likely to 
get HPV and to stay infected with it. This may, in turn, increase the risk of vulvar pre-
cancer and cancer.  
Women with cervical cancer also have a higher risk of vulvar cancer. This is 
probably because these cancers share certain risk factors like HPV infection, smoking 
and tobacco abuse.  
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MOLECULAR RISK ASSESSMENT FOR VULVAR CANCER: 
 In a review by Knopp et al data from the Norwegian Radium Hospital showed 
that p16,p21,p14,p53,VEGF,EGFR,TGF-alpha are the pathological markers of 
disease progression and outcome. But due to lack of multivariate analysis in a 
majority of the studies, no conclusion regarding the prognostic value can be drawn. 
Tumour ploidy is an important prognostic factor. 5 –year crude survival rate was   
62% for diploid and 23% for aneuploid tumours.  
PREVENTION: 
The risk of vulvar cancer can be reduced by avoiding certain risk factors and 
by treating pre-cancerous conditions before an invasive cancer develops. These steps 
cannot guarantee prevention but can greatly reduce your chances of developing vulvar 
cancer. Certain types of sexual behavior increase a woman's risk of getting a genital 
HPV infection, such as: 
¾ Having sex at an early age 
¾ Having many sexual partners 
¾ Having a partner who has had many sex partners 
¾ Having sex with uncircumcised males 
Delaying sex until older enough can help to  avoid HPV and reduces the risk 
of vulvar cancers.  
A vaccine called Gardasil protects against infection with HPV subtypes 16 and 
18 (as well as 6 and 11).  In studies, this vaccine was found to prevent anal and genital 
warts caused by HPV types 6 and 11 and to prevent anal, vulvar, vaginal, and cervical 
cancers and pre-cancers caused by types 16 and 18. This vaccine can only be used to 
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prevent HPV infection and it does not help treat an existing infection. To be most 
effective, the vaccine should be given before a woman becomes sexually active. 
Cervarix, another HPV vaccine available can also be used to prevent infection with 
HPV types 16 and 18, but it prevents cervical cancers and pre-cancers and not any of 
the other cancers linked to HPV infection such as vulvar cancer. 
There is no standard screening for this disease other than routine physical 
examinations.  
Revolution that has occurred in the treatment of this disease. There is no other 
gynaecological cancer that has undergone so much change in management as vulvar 
cancer. After the pioneering work of TAUSSIG in United States and WAY in Great 
Britain, en bloc radical vulvectomy and bilateral dissection of groin and pelvic nodes 
using “Triple incision” technique is the standard treatment of operable vulvar cancers. 
The trend is towards individualization of treatment for all patients. 
 The primary vulvar lesion can be effectively treated by radical local excision 
thereby sparing the psychosexual consequences of radical vulvectomy in most 
patients with T1 tumors. Local recurrence occurs in up to 10% cases whether or not 
radical vulvectomy has been performed and can usually be effectively treated by 
further surgery and/or radiation. By contrast, recurrence in the groin is usually fatal, 
so any patient with a T1 lesion and more than 1 mm stromal invasion should have at 
least an ipsilateral inguinal-femoral lymphadenectomy performed. For advanced T2 
and T3 tumors treatment is radical vulvectomy with inguino-femoral 
lymphadenectomy followed by closure of defects by skin grafts or chemoradiation.for 
advanced T3 and T4 disease pelvic exenteration in addition is performed. 
Postoperative groin and pelvic radiation should be given for patients with 3 or more 
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micrometastases in lymph nodes, one macrometastasis (10 mm diameter), or any 
evidence of extracapsular nodal spread. Chemotherapy with cisplatin, 5 FU is of 
limited value in the management of vulvar cancer.  
 The future role of sentinal node lymphatic mapping to decrease the morbidity 
associated with complete inguino-femoral lymphadenectomy awaits further 
investigation and trials20. 
 
 
 
 
 
 
Well  differentiated squamous cell Ca vulva Stage II 
 
 
 
 
 
Well  differentiated squamous cell Ca vulva Stage III 
23 
 
  
 
 
 
 
 
 
RESULTS & ANALYSIS 
 
 
RESULTS AND ANALYSIS 
 
Type of vulvar disease      No. of cases 
1. Infections       32 
2. Inflammatory Diseases     33 
3. Benign Cysts/Lesions      12 
4. Premalignant & Malignant Lesions    12 
Total Cases studied      89 
INFECTIONS 
• Vulval candidiasis      29 
• Tinea Cruris        3 
INFLAMMATORY DISEASES     
• Leucoplakia       22 
• Lichen Sclerosus       6 
• Lichen simplex chronicus      3 
• Lymphedema Vulva       1 
• Post RT skin necrosis       1 
  
24 
 
BENIGN CYSTS/LESIONS 
• Bartholin’s Cyst/Abscess      7 
• Vulval Hematoma       1 
• Lipoma Vulva        1 
• Vulval Warts        1 
• Mucous Cyst        1 
• Leiomyoma Vulva       1 
MALIGNANT & PREMALIGNANT LESIONS 
VIN           2 
 CARCINOMA VULVA       10 
TOTAL NO. OF CASES STUDIED     89 
  
Post radiation skin necrosis of vulva Lymphedema of vulva 
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TABLE 1 
AGE GROUP ANALYSIS OF PATIENTS 
Age 
Group in 
years 
 
Infections 
 
Inflammatory 
Diseases 
Benign 
Lesions 
Malignant 
& Pre 
Malignant 
Total 
No. of 
cases 
P Value 
30-39 20(62.5%) 1 7 (58.3%) 2 30 
0.000 
(<0.001) 
Highly 
Signific
ant 
40-49 8 12 (36.4%) 2 2 24 
50-59 3 14(42.4%) 2 …. 19 
60-69 1 4 --- 5(41.7%) 10 
70 & 
above --- 2 1 3(25.0%) 6 
Total No. 
Cases 
Disease 
Wise 
32 33 12 12 89 
 Out of 89 women in the study about 33.71% belonged to the age of 30-39 
years. The youngest and oldest age encountered was 30 years and 75 years 
respectively. (Range: 30 -75) with median of 45 years.  
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TABLE 2 
 
SOCIO ECONOMIC STATUS ANALYSIS 
 
 
Monthly Income 
in Rs. 
No. of Cases % p Value 
< Rs.500 14 15.7 
0.000 (<0.001 
highly significant) 
Rs.500 - 1000 22 24.7 
Rs.1000 - 1500 37 41.6 
Rs.1500 – 2000 12 13.5 
Rs.2000 & more 4 4.5 
TOTAL 89 100.0 
 
 
Majority of women belonged to the low income group of < Rs.1500 per month with 
41.6% of cases in the range of Rs.1000 – 1500 per month. The p value of this 
observation is 0.000 (<0.001 highly significant). 
  
28 
 
CHART 2 
ANALYSIS OF EDUCATIONAL STATUS 
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TABLE 3 
ANALYSIS OF MENSTRUAL STATUS  
OF WOMEN IN THE STUDY 
 
Menstrual 
Status Infections 
Inflammatory 
Diseases 
Benign 
Cysts 
Malignant & 
Premalignant Total p value 
Reproductive & 
perimenopausal 28(87.5%) 10 
8.(66.7
%) 2 48 
0.000 
(<0.001 
highly 
signific
ant) 
Postmenopausal 4 23 (69.7%) 4 10 (83.3%) 41 
Total 32 33 12 12 89 
 
 There were 48 and 41 cases in the reproductive, perimenopausal and 
postmenopausal groups respectively. 87.5% of infections and 66.7% of benign 
cysts/lesions were common in the former group and 69.7% of inflammatory diseases 
and 83.3% of malignant and premalignant diseases were common in the latter group 
with a highly significant p value of 0.000. 
  
30 
 
CHART 3 
ANALYSIS OF MARITAL STATUS 
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CHART 4 
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TABLE 4 
PARITY ANALYSIS OF STUDY POPULATION 
Parity No. of cases 
of Malignant 
& 
Premalignant 
diseases  
% No. of 
cases of 
Other 
vulvar 
diseases 
% p Value 
Nullipara 3 25 1 1.3 0.000 
(<0.001 
highly 
significant) 
P1 - - 3 3.9 
P2 1 8.3 38 49.4 
P3 1 8.3 22 28.6 
≥ P4 7 58.3 13 16.9 
 
 Though P2 is the most common parity among the vulvar diseases studied, ≥ P4 
is most common parity among the women with vulvar cancer constituting 58.3% of 
all cases of carcinoma, which is a risk factor for the disease. The observation has a P 
value of 0.000. 
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TABLE 5 
ANALYSIS OF CO-MORBID CONDITIONS 
 
Co Morbid 
Conditions 
No. of cases % p Value 
Diabetes 30 33.7 0.570  
(Not Significant) 
Hypertension 13 14.6 0.003 (Significant) 
Obesity 19 21.3 0.019 (Significant) 
Immunosuppression 
(HIV Positive) 
4 4.5 0.171  
(Not Significant) 
 
 
Diabetes found in 33.7% cases especially in infection group  (11 out of 32), 
with an insignificant p value whereas hypertension and obesity seen in 14.6% and 
21.3% of cases respectively with a significant p value. 4 out of 89 cases were HIV 
positive out of which 2 was carcinoma vulva. However the p value of 0.171 is not 
significant.  
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CHART 5 
HISTORY OF PREVIOUS STI 
 
 
  
Hist
with a hig
(65.6% ie. 2
 
ory of prev
hly signific
1 out of 32
ious sexua
ant p valu
 cases).  
 
60
HI
lly transmi
e of 0.000
STORY OF
Prese
tted infectio
 especially
 PREVIOU
nt Abse
29
S STI
nt
 
ns seen in 
 seen in t
29 out of 8
he infectio
9 cases 
n group 
35 
 
TABLE 6 
Risk Factors No of cases Percentage p Value 
Smoking 3 3.4 0.365 (Not 
significant) 
Tobacco Abuse 21 23.6 0.000 (highly 
significant) 
None 65 73.0  
 
CHART 6 
3
21
65
SMOKING AND TOBACCO ABUSE ‐
ANALYSIS OF RISK FACTORS
Smoking Tobacco Abuse None
 
 3 out of 89 women had the habit of smoking with an insignificant p value of 
0.365 whereas tobacco abuse seen in 21 cases (23.6%) with a significant p value of 
0.000. Out of the tobacco abusers 10 cases had malignant and premalignant diseases. 
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TABLE 7 
ANALYSIS OF SEXUAL PROMISCUITY 
 
 
Type of 
Promiscuity 
No. of cases Percentage p value 
Extramarital 4 4.49 0.011 
Premarital 8 8.99 
Both Nil 0 
Total 12 13.48 
 
  
Sexual promiscuity either extramarital contact or premarital contact found in 
13.48% of cases. Exposure to multiple sexual partners predisposes to vulvar cancer.  
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TABLE 8 
DISEASE WISE ANALYSIS OF MOST COMMON  
PRESENTING COMPLAINT 
 
Presenting 
complaint 
Infections Inflammatory 
diseases 
Benign 
Cysts 
Malignant & 
Premalignant 
p value 
Pruritus  18 (56.3%) 25(75.8%) - 2 0.000 
(<0.001 
highly 
significant) 
Mass/Ulcer - 2 9(75.0%) 10(83.3%)  
Pain - 2 3 - - 
Associated 
white 
discharge 
14(43.8%) 4 - - - 
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 TABLE 9 
DISEASE WISE ANALYSIS OF CLINICAL SIGNS 
Clinical 
Signs 
Infections Inflammatory 
Diseases 
Benign 
Cysts 
Malignant 
and 
Premalignant
Total p Value 
Discolor
ation 
32 31 - - 63 0.000 
(<0.001 
highly 
significant) 
Mass - 1 12 9 22  
Ulcer - 1 - 3 4  
 
Discoloration of vulvar skin is the most commonly seen clinical sign (63out of 
89 cases i.e. 70.8% of all cases) especially seen in the infections group and 
inflammatory diseases. Mass seen in 22 out of 89 cases especially among benign and 
malignant diseases, constituting 24.7% of all cases. This observation has a p value of 
0.000 (highly significant). 
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VULVAR LESIONS ASSOCIATED WITH OTHER  
GYNAECOLOGICAL CONDITIONS 
Leucoplakia with Ca ovary   :  1 case 
Leucoplakia with Ca cervix (Post EBRT) : 3 cases 
Ca Vulva with UV prolapse   : 1 case 
 
 
 
 
 
 
Poorly diff. squamous cell Ca Vulva Stage III with UV prolapse 
 
 
 
 
 
 
Leucoplakia simple squamous hyperplasia 
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PAPANICOLAOU SMEAR REPORTS 
Total PAP smears taken   : 87 
Normal smears    : 45 
Inflammatory smears    : 19 
Atrophic smears    : 23 
ALL WERE NEGATIVE FOR SIL (Squamous Intraepithelial Lesions) 
No associated CIN lesions in any of the cases. 
 KOH SMEAR STUDY 
Total No. of KOH smears taken  : 63 
NO. of smears positive for candidiasis : 29 
  
Vulvoscopic – acetowhite areas on vulva 
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VULVOSCOPIC ANALYSIS – HPE REPORTS 
Total No. of Vulvoscopy done : 65 
Normal Study : 32 
Abnormal Study : 33 
• VIN III : 2 
• Simple squamous hyperplasia (SSH) : 19 
• SSH with mild dysplasia : 2 
• SSH with moderate dysplasia : 1 
• Lichen simplex chronicus : 3 
• Lichen sclerosus : 6 
• Lichen Planus : 0 
 
 
 
 
 
 
 
 
 
 
SSH with moderate dysplasia    Lichen simplex chronicus 
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TREATMENT ANALYSIS 
Vulval Disease No. of Cases Treatment Given 
Vulval candidiasis  
Tinea Cruris 
32 
Oral Fluconazole 150 mg 
single dose + 
Clotrimazole ointment 
twice daily application 
for 2 weeks 
Benign Cysts Lesions 12 
Excision / 
Marsupialisation 
Simple squamous 
hyperplasia only  19 
Topical steroid ointment 
Clobetasole twice daily 
for 2 weeks 
Simple squamous 
hyperplasia with mild 
dysplasia 2 cases 
1 
Topical steroid ointment 
Clobetasole twice daily 
for 2 weeks. Follow up 6 
months later. 
Simple squamous with 
moderate dysplasia 
1 
Simple vulvectomy done 
Lichen Sclerosus 1 out of 6 Simple vulvectomy 
 
5 out 6 
Topical steroid ointment 
Clobetasole twice daily 
for 2 weeks. Follow up 6 
months later. 
Lichen Simplex 
chronicus 3 
Topical steroid ointment 
Clobetasole twice daily 
for 2 weeks, antibiotics, 
followup. 
Post RT skin necrosis 1 Analgesics, Observation 
Vulvar lymphedema 1 Observation 
VIN III 2 Wide local Excision 
Carcinoma Vulva 2 Surgery only 
 4 Palliative Radiation only 
 3 Surgery + Post of RT 
 1 Lost to follow up 
                                                  
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
DISCUSSION 
In our study of 89 women with vulvar diseases the analysis of cases done by 
categorizing them into 4 major groups. Infections constituting 35.96% (32 cases out 
of 89), inflammatory diseases 37.08% (33 cases out of 89), benign cysts/lesions in 12 
out of 89 cases constituting 13.48% and premalignant and malignant diseases of vulva 
in 12 out of 89 cases forming 13.48%. 
Age of the women ranged from 30 years to 75 years with a median age of 45 
years. Out of 89 cases 41 of them were postmenopausal constituting 46.07% of cases. 
In a study on clinico-pathological analysis of vulvar diseases over 5 years in Kolkata 
in India between 2000-2005 about 80% were postmenopausal out of 55 women 
included in the study. 
The epidemiological risk factors of cancer vulva are similar to those of cancer 
cervix. About 41.6% of women in our study had a monthly income of Rs.1000 to 
Rs.1500 belonging to the low economic status and about 37.1% being illiterates both 
of which are contributing factors for the development of cancer vulva. 
Infections especially vulvar candidiasis seen most commonly in the younger 
women of 30-39 years of age (20 out of 32 cases).This corroborates with the 
epidemiological study conducted in India in 2007 on 350 women in which there was a 
consistent increase in incidence of VVC in the 2nd to 4th decades of life especially 
among the women of low socio-economic status and poor personal hygiene. It is well 
known that there is an association between VVC and diabetes. In this study diabetes 
was found in 11 out of 32 cases in the infection group (34.4%). 
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Vulvar warts are strongly associated with HPV infections 6, 11. We had only 
one case of condyloma accuminatum. There was no associated cervical pathology in 
that patient whereas a study on correlative analysis of cervical lesions in patients with 
vulvar condylomas by Qing et al in 418 cases over 2 years (2002-2004) showed that 
20.6% cases had high risk HPV infection with cervical lesions. 
Lichen Sclerosus has two peak ages of presentation. The 1st group in pre-
menarcheal girls who are not included in our study and the 2nd peak in 
postmenopausal women. In our study, we had 6 cases of histology proven LS out of 
which 4 were postmenopausal women. In a clinical study by Singh et al in India 
between 2005-2007 out of 26 cases in the study the mean age was 44 years with 
pruritus being the most common symptom with a median duration of 2.5 years. 
Similarly in our study also the mean age was 47.7 years with pruritus being the 
predorminant symptom seen in 5 out of 6 cases (83.3%) and a median duration of 11 
months. None had any previous history of any autoimmune disorders. 
Lichen Sclerosus- atrophy of labia majora                          SSH-mild dysplasia  
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 In our study we had only 3 cases of Lichen Simplex Chronicus (3.37%) with 
the mean age of 55.3 years and a median duration of 12 months and all of them 
presented with pruritus as the most common complaint. In a study on the pattern of 
non-venereal dermatosis of vulva in South India in 2008, out of 120 cases in the study 
population, 16 had LSC (13.3%) with a mean age of 49.9 years and a median duration 
of 2 years. 
Lichen Planus is well-known inflammatory dermatoses affecting the mucosa 
of vulva and vagina but we did not report any case due to the low prevalence of the 
condition. 
In our study we had 7 cases of Bartholin’s cysts/abscess out of which 4 cases 
were in the reproductive age group and 3 cases were postmenopausal. The mean age 
of presentation was 46.5 years and the median duration was 0.25 months. 4 cases 
presented with mass as the presenting complaint whereas it was pain in the vulva in 
the remaining 3 cases.  We had one case the rare entity of leiomyoma vulva in a 37 
year old woman who presented with mass in the vulva of 8 years duration.  
 
 
 
 
 
Benign Leiomyoma of Vulva 
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There were 2 cases of VIN III , a pre-malignant disease of vulva with a mean 
age of presentation of 64 years and a median duration of symptoms of 9 months and 
presented with  unifocal mass in the vulva especially in the labia majora.  Both were 
postmenopausal women with the risk factor of tobacco abuse. They were treated with 
wide local excision. In a study of 293 women with VIN, Basta et al reported that 
women > 45 years had unifocal lesions (68.2%) with chronic itch-scratch-itch cycle 
similar to our patients.  
In our study we had 10 cases of cancer vulva belonging to the age group of 36 
to 75 years with a mean age of 57.4 years. 8 out of 10 cases belonged to 
postmenopausal group with mass in the vulva being the presenting complaint in 9 out 
of 10 cases. The duration of symptoms varies from 4 months to 4 years and median of 
2 years. Risk factors like low income of < Rs.500 ( 6 cases), illiteracy (10cases), HIV 
+ve  in 2 patients, tobacco abuse in 8 out of 10 cases, higher order parity of >= P4 in 6 
cases. 7 cases presented with mass (70%) and rest of the 3 cases with ulcer in the 
vulva (30%). Histologically 5 were well differentiated squamous cell Ca (including 
one rare case of Verrucous cell Ca) and the rest of the 5 cases were poorly 
differentiated squamous cell Ca. As per FIGO Clinical staging the stage of the disease 
varied from stage 2 to stage 4 (3 cases in stage II, 5 cases in stage III and 2 cases in 
stage IV). Inguinal nodes were palpable in 4 cases in one or both sides. 
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Well differentiated verrucous squamous cell  carcinoma Stage II  
  
 
 
 
Well differentiated squamous cell Ca vulva stage II. 
 
 
 
 
 
 
 
Poorly  differentiated squamous cell Ca vulva Stage III with inguinal nodes 
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SUMMARY 
 
 
 
 
SUMMARY 
89 symptomatic women attending the gynaec clinic at our institute were the 
participants of this study. After obtaining the informed consent they were subjected to 
a detailed history taking and physical examination. Data on their age distribution, 
socio-economic status, education, menstrual and marital history including sexual 
history, personal hygiene were studied and analysed. 
 Pap smear was offered to 87 cases and associated cervical pathology ruled 
out. All were negative for squamous intraepithelial lesions or CIN. 63 patients with 
pruritus with or without associated white discharge were tested for the presence of 
fungal infections using KOH smears and those cases with infections were treated with 
oral and topical antifungals. 
 Vulvoscopy performed in 65 patients showed it to be normal in 32 cases and 
abnormal in 33 cases including 2 patients with VIN III, 6 cases with Lichen sclerosus, 
3 cases with Lichen simplex chronicus, 22 cases with simple squamous hyperplasia 
with or without dysplasia.Both the VIN III treated with wide local excision with 1 cm 
free margins. Simple Vulvectomy for a case of lichen simplex chronicus and another 
for a case of simple squamous hyperplasia with moderate dysplasia, both had intense 
pruritus disturbing the quality of life of patients. All others were treated with topical 
steroids and awareness created about the need for follow up. 
 Out of the 10 cases of Carcinoma vulva one patient was lost to follow up after 
the initial visit. Of the rest of the biopsy proven cases clinical staging showed 3 cases 
with stage II, 5 cases with stage III &   rest of the 2 cases in stage IV. Of the 10 cases 
four had palpable inguinal nodes on one or both sides. 
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Well differentiated sq cell Ca 
vulva stage IV with inguinal nodes Poorly differentiated sq cell Ca vulva stage IV with inguinal nodes
 Radical vulvectomy with bilateral inguino-femoral groin dissection with or 
without post- operative radiotherapy is the standard treatment of choice for invasive 
vulvar carcinomas. Two cases with negative nodes and > 1cm tumour free margin 
with complete resection of the tumour were treated with surgery only. 3 cases with 
positive nodes and narrow tumor-free margins of < 8mm were subjected to post-op 
adjuvant radiotherapy. 4 patients with poor performance status and who were unfit for 
surgery were treated with palliative radiation, external beam radiotherapy. In our 
study patients’ participation and co-operation was encouraging. 
This study also helped to create awareness among women regarding the 
modifiable risk factors and the benefits of early detection and treatment in reducing 
the morbidity and mortality due to the invasive disease. Vulvoscopy screening at 
every gynaec clinic will help us in early detection and  prompt treatment of patients 
with pre-cancerous lesions as well.  
 
 
  
 
 
 
 
 
 
CONCLUSION 
 
 
CONCLUSION 
Worldwide about 60% of all vulvar cancers occur in developing countries like 
India. There is a rise in insitu cancers among the younger women due to increasing 
HPV prevalence and the related VIN.  
Factors such as smoking, tobacco abuse, immunosuppression, sexual 
promiscuity are key contributors which can be modified. Hence there is a need to 
create awareness among the women regarding the etiology, risk factors and malignant 
potential of some vulvar diseases. At present there is no specific widespread screening 
program  for vulvar cancers like the cervical neoplasm. Vulvoscopy is an excellent 
triage tool for defining suspicious lesions and it should be made available in all 
headquarters hospitals and tertiary centers. Gynecologists are to be trained adequately 
in vulvoscopic methods so as to enable early diagnosis with high index of suspicion. 
Broad dissemination of HPV prevention vaccine has the potential to reduce HPV 
related vulvar cancers in young women. Management of women with chronic vulvar 
diseases has been one of the most challenging aspects for a long time. This study will 
help focus the direction of further research studies on the early diagnosis and 
treatment of vulvar diseases. 
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PROFORMA 
 
A  CLINICAL STUDY ON VULVAR DISEASES AMONG 
SYMPTOMATIC PATIENTS ATTENDING GYNAEC OP IN 
THE INSTITUTE OF OBSTETRICS AND GYNAECOLOGY, 
CHENNAI. 
 
PROFORMA 
NAME  AGE:                      IP NO                      DATE: 
PARA                      LIVE                      ABORTIONS 
EDUCATION     : 
SOCIOECONOMIC STATUS  : 
COMPLAINTS    : 
 H/O pruritus     : Yes / No               
H/O mass in the vulva   :  Yes / No 
Duration 
Site 
Size 
Bleeds on touch  
H/O pain in vulval region   : Yes / No 
 
 
H/O discharge P/V    : Yes / No 
 Duration 
 Amount 
 Colour 
 Odour 
 Consistency 
 Associated with Itching 
MENSTRUAL HISTORY  
Menarche at     :  
Regular / Irregular 
Clothes / Napkins 
Disposal / Reused/detergents 
LMP 
Menopause at     :  
Postmenopausal bleeding  :   Present / Absent 
MARITAL HISTORY: 
Married since    - 
Living with husband or not  - 
H/O previous marriages  - 
H/O premarital /extramarital  - 
   contacts 
  
  
 
OBSTETRIC HISTORY     
Para  Live  LCB  : 
Sterilised or Not    : 
Mode of delivery    : 
Age of first child birth-   : 
 
PERSONAL HISTORY    
H/O personal hygiene    : 
H/O Smoking / Tobacco              : 
H/O drug abuse    : 
SEXUAL HISTORY   
Age of first intercourse   : 
Coital frequency    : 
Type of sex(Oral/Vaginal/Anal)  : 
Exposure to commercial sex workers  :   
PAST HISTORY: 
H/O previous Gynaecological problems : 
H/O previous Pap smear   : 
H/O previous Colposcopy   : 
H/O STI and treatment if any   : 
H/O Past medical(diabetes) / SurgicaL    :  
 
FAMILY HISTORY 
GENERAL EXAMINATION                                             
 Height     :  Weight   :    BMI   : 
Built – Thin / Moderate / Obese 
Febrile / Afebrile  
Pallor - Present / Absent 
Icterus-Present/Absent 
Pedal Edema – Present / Absent 
Skin Lesions – Present / Absent 
Lymph nodes enlargement 
 
SYSTEMIC EXAMINATION               
CVS 
RS 
Abdomen 
LOCAL EXAMINATION             
Swelling 
Discoloration                     Erythema/   Leucoplakia 
Ulcers                                 Single or Multiple 
                                           +/- Induration  
 
           +/_Necrotic slough 
 
 
SPECULUM EXAMINATION   
PAPSMEAR 
 BIMANUAL EXAMINATION   
Cervix position up / down 
Uterus anteverted / retroverted             
Uterus normal size / bulky 
Fornices free/tenderness 
PER RECTAL EXAMINATION  
Parametrium     
Rectal Mucosa 
VULVOSCOPIC EXAMINATION   
VULVAL BIOPSY     
HISTOPATHOLOGICAL REPORT   
ANALYSIS       
The data collected are analysed statistically using SPSS software (version 15) 
with Chi square tests as the tools used and the vulvar diseases studied.  
 
 
 
 
 
  
 
 
 
 
 
CONSENT FORMS 
 
A  CLINICAL STUDY ON VULVAR DISEASES AMONG 
SYMPTOMATIC PATIENTS ATTENDING GYNAEC OP IN 
THE INSTITUTE OF OBSTETRICS AND GYNAECOLOGY  
PATIENT CONSENT FORM PART I 
 Vulvar problems account for a significant numbers of patients attending 
gynaec OP. The vulvar carcinoma continues to rise in incidence in recent years. 
Therefore attempts to reduce this cancer must focus on recognizing precursor lesions 
like VIN, Lichen Sclerosus which could progress to carcinoma if left untreated. 
 This study aims to evaluate the disease among symptomatic patients attending 
gynaec OP at our institute, a tertiary care centre. 
 Vulvoscopy offers an excellent opportunity in clinical gynaecologic practice 
for defining and delineating cytologically defective lesions of the vulva and for early 
diagnosis of the disease. 
 For this observational study, all participants are to receive  a complete 
gynaecological examination including colposcopic evaluation and a structured 
interview about socioeconomic characteristics and risk factors for vulvar diseases. 
RISK TO THE PATIENT 
 There is no known risk to the patients participating in the study. The data will 
be obtained from the patients and their case records currently used in the department. 
  
 
PATIENT CONSENT FORM - PART II 
STUDY TITLE: A clinical study on vulvar disease among symptomatic patients 
attending gynaec OP in Institute of Obstetrics and Gynaecology, Chennai. 
STUDY CENTRE : Department of Obstetrics and Gynaecology, Institute of  
    Obstetrics and Gynaecology, Egmore, Chennai – 8. 
     Patients may check(9) these boxes. 
PARTICIPANT NAME: 
I confirm that I have understood the purpose of the above 
study. I have the opportunity to ask questions and all my 
questions and doubts have been answered to my complete 
satisfaction. 
I understand that my participation in the study is voluntary 
and that I am free to withdraw at any time without giving 
any reason, without my legal rights being affected. 
I understand that investigator, the institution, regulatory 
authorities and the ethics committee will no need my 
permission to look at my health records both in respect to 
the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the 
study. I understand that my identity will not be revealed in 
any information released to third parties or published, 
unless as required under the law. I agree not to restrict the 
use of any data or results that may arise from this study. 
 
I hereby consent to undergo complete physical examination 
and diagnostic tests including hematological, biochemical, 
radiological examinations. 
I agree to take part in the above study and to comply with 
the instructions given during the study and to faithfully co-
operate with the study team and to immediately inform the 
study staff if I suffer from any deterioration in my health. 
I hereby consent to participate in this study of “ A clinical 
study on vulvar diseases among symptomatic patients 
attending gynaec OP in Institute of Obstetrics and 
Gynaecology, Chennai”. 
Signature of the Patient/Thumb impression:…………… 
Place   Date   Address 
Signature of the investigator……………………………… 
Place    Date   Address. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
ABBREVIATIONS
 
ABBREVIATIONS 
HPV    :   Human Papilloma Virus 
HIV    :  Human Immuno-deficiency Virus 
VVC    :   Vulvo Vaginal Candidiasis 
OPD    :   Out Patient Department 
IOG    :  Institute of Obstetrics and Gynaecology, 
      Chennai 
 VIN    :  Vulvar Intraepithelial Neoplasia 
CIN    :  Cervical Intraepithelial Neoplasia 
LS    :  Lichen Sclerosus 
LSC    :  Lichen Simplex Chronicus 
LP    :  Lichen Planus 
SCC    :  Squamous Cell Carcinoma 
SEER    :  Surveillance, Epidemiology and End- 
      Results 
ISSVD   :  International Society for the Study of  
      Vulvar Diseases 
RT    :  Radiotherapy 
CT    :  Chemotherapy 
VEGF    :  Vascular Endothelial Growth Factor 
 
 TGF    :  Transforming Growth Factor 
OP/IP    :  Outpatient/In patient 
SES    :  Socio Economic Status 
EDN    :  Educational status 
STI    :  Sexually Transmitted Infection 
EMC    :  Extra Marital Contact 
PMC    :  Pre Marital Contact 
SSH    :  Simple Squamous Hyperplasia 
KOH    :  Potassium Hydroxide 
HPE    :  Histo -Pathological Examination 
 
 
 
 
 
 
  
 
 
 
 
 
MASTER CHART 
 
 
 
MASTER CHART 
 
IP/OP 
NO AGE 
SES  
monthly 
EDN 
STATUS 
MENSTRUAL 
St. PARITY COMPLAINTS DURATION DM HT OB HIV + OTHERS 
11543 56 500-1000 illiterate postmenopausal P3L3 mass 0.5 months  +  +   + 
11673 57 500-1000 illiterate postmenopausal P2L2 pruritus 3 months 
11383 30 1000-1500 HSc menstruating nullipara mass 0.25 months 
10437 40 1000-1500 HSc menstruating P2L2 pruritus 2 months 
22082 32 1000-1500 upto 10th menstruating P2L2 discharge p/v 0.5 months 
13209 42 1000-1500 upto 10th menstruating P3L3 pruritus 12 months 
21074 56 500-1000 illiterate postmenopausal P3L3 discharge p/v 2 months  +  + 
16612 60 <500 illiterate postmenopausal P7L5 pruritus 48 months  + 
22832 33 1000-1500 upto 10th menstruating P2L2 pruritus 3 months  + 
14213 65 500-1000 illiterate postmenopausal P4L4 pruritus 12 months 
26842 60 1000-1500 upto 10 th Postmenopausal P2L2 discharge p/v 6 months 
26821 38 1000-1500 upto 10 th menstruating P3L3 discharge p/v 3 months  + 
15774 55 <500 illiterate postmenopausal P4L4 discharge p/v 6 months 
16978 36 1000-1500 illiterate menstruating nullipara mass 24 months  + 
15760 73 <500 illiterate postmenopausal P8L6 mass 12 months  + 
24806 32 1500-2000 HSc menstruating P2L2 discharge p/v 10 months 
10977 65 <500 illiterate menstruating P7L3 mass 4 months  +  
15462 72 <500 illiterate postmenopausal P4L3 discharge p/v 4 months  +  +  CA CERVIX 
 
IP/OP 
NO 
H/O 
STI SEX H/O SMOK TOB CLINICAL SIGNS INVESTIGATION HPE REPORT TREATMENT 
11543  + mass blood sugar bartholin's cyst/abscess incision&drainage 
11673 discoloration biopsy leucoplakia SSH steroids 
11383 mass routine blood vulvar hematoma evacuation 
10437 premarital discoloration biopsy leucoplakia SSH steroids 
22082 discoloration KOH mount vulvar candidiasis antifungals 
13209 premarital discoloration biopsy leucoplakia SSH steroids 
21074 discoloration KOH mount vulvar candidiasis antifungals 
16612  + mass biopsy well diff sq cell ca STAGE II radiotherapy  
22832 discoloration KOH mount vulvar candidiasis antifungals 
14213 premarital  + discoloration biopsy leucoplakia SSH steroids 
26842 discoloration KOH mount vulvar candidiasis antifungals 
26821 discoloration KOH mount vulvar candidiasis antifungals 
15774  + discoloration biopsy leucoplakia SSH steroids 
16978 extramarital  + mass biopsy well diff sq cell ca STAGE III surgery+RT 
15760  + mass biopsy well diff sq cell ca STAGE II surgery only 
24806  + discoloration KOH mount vulvar candidiasis antifungals 
10977  + mass biopsy verrucous well diff sq cell STAGE II surgery only 
15462  +  + discoloration biopsy leucoplakia SSH steroids 
 
 
 
 
IP/OP 
NO AGE 
SES  
monthly 
EDN 
STATUS 
MENSTRUAL 
St. PARITY COMPLAINTS DURATION DM HT OB 
HIV 
+ OTHERS 
28802 31 1500-2000 graduate menstruating P2L2 pruritus 6 months 
24621 48 1000-1500 upto 10 th postmenopausal P3L3 pruritus 3 months  +  +  +   
8556 48 500-1000 illiterate postmenopausal P1L1 mass 12 months  CA CERVIX 
18467 37 > 2000 graduate menstruating P2L2 mass 96 months 
20382 62 <500 upto 10th postmenopausal P1L1 discharge p/v 12 months  + 
10824 55 500-1000 upto 10 th postmenopausal P4L4 pain 1 month  CA CERVIX 
21086 53 500-1000 illiterate postmenopausal P3L3 pruritus 6 months  +  +  + 
28155 70 <500 illiterate postmenopausal P6L6 mass 0.33 months  + 
21072 54 1000-1500 upto 10 th postmenopausal P3L3 pruritus 4 months 
26234 44 1000-1500 upto 10 th menstruating P2L2 discharge p/v 2 months 
24682 50 500-1000 upto 10 th menstruating P2L2 pruritus 3 months 
11581 70 < 500 illiterate postmenopausal P6L5 mass 12 months  + 
29256 69 <500 illiterate postmenopausal P4L4 pruritus 12 months  +  + 
20826 66 <500 illiterate postmenopausal P8L6 mass 24 months  + UV PROLAPSE 
7682 40 1000-1500 HSc menstruating P2L2 discharge p/v 6 months  +  + 
26381 53 1000-1500 illiterate postmenopausal P6L6 pruritus 12 months  + 
18245 38 1000-1500 upto 10 th menstruating P2L2 discharge p/v 12 months 
29517 47 1000-1500 illiterate postmenopausal P2L1 mass 12 months 
23928 33 1000-1500 upto 10th menstruating P2L2 mass 12 months 
 
 
 
IP/OP 
NO H/O STI SEX H/O SMOK TOB CLINICAL SIGNS INVESTIGATION HPE REPORT TREATMENT 
28802  + discoloration KOH mount vulvar candidiasis antifungals 
24621  +  + discoloration KOH mount vulvar candidiasis antifungals 
8556  + mass routine blood lymphedema vulva observation 
18467 mass routine blood leiomyoma excision 
20382  + discoloration biopsy leucoplakia SSH steroids 
10824 ulcer routine blood post RT skin necrosis antibiotics,analgesics 
21086  + discoloration biopsy lichen simplex chronicus steroids 
28155  + mass blood sugar bartholin's cyst/abscess incision&drainage 
21072 discoloration biopsy leucoplakia SSH steroids 
26234  + discoloration KOH mount vulvar candidiasis antifungals 
24682 discoloration biopsy leucoplakia SSH steroids 
11581  + ulcer biopsy 
poorly diff sq cell ca STAGE 
III radiotherapy  
29256  + discoloration biopsy leucoplakia SSH mild dysplasia steroids 
20826  + mass biopsy 
poorly diff sq cell ca STAGE 
III lost to follow up 
7682  + discoloration KOH mount vulvar candidiasis antifungals 
26381 discoloration biopsy leucoplakia SSH steroids 
18245  + discoloration KOH mount vulvar candidiasis antifungals 
29517 discoloration biopsy 
leucoplakia SSH moderate 
dysplasia simple vulvectomy 
23928 mass biopsy vulvar warts observation,follow up 
 
 
 
IP/OP 
NO AGE 
SES  
monthly 
EDN 
STATUS 
MENSTRUAL 
St. PARITY COMPLAINTS DURATION DM HT OB HIV + OTHERS 
22998 37 1000-1500 upto 10th menstruating P2L2 mass 6 months 
21862 36 1000-1500 upto 10th menstruating P3L3 discharge p/v 3 months 
20461 45 1000-1500 upto 10th menstruating P3L3 mass 0.25 months 
24601 31 1000-1500 HSc menstruating P1L1 pruritus 0.75 months 
22943 41 1500-2000 upto 10th menstruating P2L2A1 discharge p/v 4 months  + 
23841 43 1000-1500 HSc menstruating P2L2 pruritus 12 months 
21208 58 1000-1500 illiterate postmenopausal P5L4A2 pruritus 12 months  +  + 
16050 30 >2000 graduate menstruating P2L2 pain 0.25 months  + 
24962 60 1000-1500 illiterate postmenopausal P3L3 pruritus 12 months  + 
23821 32 1500-2000 upto 10th menstruating P2L2 pruritus 6months 
30213 58 500-1000 upto 10th postmenopausal P4L4 pruritus 6 months  +  + 
24682 36 1500-2000 HSc menstruating P2L2 discharge p/v 6 months 
26684 38 1500-2000 Upto 10 th menstruating P3L3 discharge p/v 12 months 
28213 53 1000-1500 illiterate postmenopausal P4L4 pruritus 24 months  +  + 
22103 68 500-1000 illiterate postmenopausal P3L3 pruritus 12 months  + 
26824 56 <500 upto 10 th postmenopausal P6L3 mass 24 months 
18024 32 <500 HSc menstruating P2L2 pruritus 6 months 
28468 60 500-1000 illiterate postmenopausal P5L4 mass 6 months  + 
28461 52 1000-1500 illiterate menstruating P3L3 discharge p/v 3 months  +  +  + 
30483 45 500-1000 illiterate postmenopausal P6L6 mass 12 months 
 
 
 
 IP/OP NO 
H/O 
STI SEX H/O SMOK TOB CLINICAL SIGNS INVESTIGATION HPE REPORT TREATMENT 
22998 mass biopsy mucous cyst excision 
21862  + discoloration KOH mount vulvar candidiasis antifungals 
20461  + mass blood sugar bartholin's cyst/abscess incision&drainage 
24601 discoloration KOH mount tinea cruris antifungals 
22943 discoloration KOH mount vulvar candidiasis antifungals 
23841 premarital discoloration biopsy leucoplakia SSH steroids 
21208 premarital  + discoloration biopsy leucoplakia SSH steroids 
16050 mass biopsy bartholin's cyst/abscess incision&drainage 
24962  + discoloration biopsy leucoplakia SSH steroids 
23821  + discoloration KOH mount tinea cruris antifungals 
30213 discoloration biopsy leucoplakia SSH steroids 
24682 discoloration KOH mount vulvar candidiasis antifungals 
26684  + discoloration KOH mount vulvar candidiasis antifungals 
28213  + discoloration KOH mount vulvar candidiasis antifungals 
22103  + mass biopsy VIN III wide local excision 
26824 mass routine blood vulvar lipoma excision 
18024  + discoloration KOH mount vulvar candidiasis antifungals 
28468  + mass biopsy VIN III wide local excision 
28461  + discoloration KOH mount vulvar candidiasis antifungals 
30483  + ulcer biopsy 
poorly diff sq cell ca 
STAGE III radiotherapy  
 
 
IP/OP 
NO AGE 
SES  
monthly 
EDN 
STATUS 
MENSTRUAL 
St. PARITY COMPLAINTS DURATION DM HT OB HIV + OTHERS 
31513 38 1000-1500 upto 10 th menstruating P2L2 pruritus 1,5 months  +  + 
27347 37 1000-1500 illiterate menstruating P2L2 mass 0.25 months  +  + 
30102 35 1500-2000 graduate menstruating P3L2A1 pruritus 12 months  +  + 
29633 37 1000-1500 illiterate menstruating nullipara mass 24 months  + 
21386 48 1000-1500 illiterate postmenopausal P3L3 pruritus 8 Months 
28543 33 1500-2000 graduate menstruating P2L2 pruritus 5 months  + 
25348 54 1000-1500 illiterate postmenopausal P4L4 discharge p/v 24 months  + 
18439 42 1000-1500 HSc menstruating P2L2 pruritus 1 month 
20456 31 1500-2000 upto 10 th menstruating P2L1 pruritus 6 months 
15349 75 <500 illiterate postmenopausal P3L3 pruritus 12 months 
33038 75 <500 illiterate postmenopausal P2L2 mass 24 months  +  + 
31286 40 500-1000 upto 10 th menstruating P3L3 pruritus 12 months 
20828 32 1000-1500 HSc menstruating P2L2 pruritus 6 months  + 
21282 55 500-1000 upto 10 th postmenopausal P2L2 pruritus 12 months  + 
28145 30 1000-1500 HSc menstruating P2L2 pruritus 0.25 months 
20842 55 500-1000 HSc postmenopausal P3L3 pruritus 24 months  + 
27402 32 >2000 graduate menstruating P2L2A1 pruritus 1,5 months 
14387 45 1000-1500 upto 10th  menstruating P3L3 pruritus 3 months  + 
18692 40 500-1000 upto 10 th menstruating P2L2A2 pruritus 12 months  +  + 
19806 58 500-1000 illiterate postmenopausal P4L3 pruritus 12 months 
 
 
 
IP/OP NO H/O STI SEX H/O SMOK TOB CLINICAL SIGNS INVESTIGATION HPE REPORT TREATMENT 
31513  + discoloration KOH mount vulvar candidiasis antifungals 
27347 mass blood sugar bartholin's cyst/abscess incision&drainage 
30102  + discoloration KOH mount vulvar candidiasis antifungals 
29633  + premarital mass biopsy well diff sq cell ca STAGE IV surgery+RT 
21386 discoloration biopsy lichen sclerosus steroids 
28543  + extamarital discoloration KOH mount vulvar candidiasis antifungals 
25348 premarital discoloration biopsy leucoplakia SSH mild dysplasia steroids 
18439  + discoloration KOH mount vulvar candidiasis antifungals 
20456  + discoloration KOH mount vulvar candidiasis antifungals 
15349 discoloration biopsy leucoplakia SSH steroids 
33038  + mass biopsy poorly diff sq cell ca STAGE III radiotherapy  
31286 discoloration biopsy leucoplakia SSH steroids 
20828 discoloration KOH mount tinea cruris antifungals 
21282 discoloration biopsy lichen sclerosus steroids 
28145 discoloration KOH mount vulvar candidiasis antifungals 
20842  + discoloration biopsy lichen simplex chronicus steroids 
27402  +   discoloration KOH mount vulvar candidiasis antifungals 
14387  + extramarital discoloration KOH mount vulvar candidiasis antifungals 
18692  + discoloration KOH mount vulvar candidiasis antifungals 
19806  + discoloration biopsy lichen simplex chronicus steroids 
 
 
 
IP/OP 
NO AGE 
SES  
monthly 
EDN 
STATUS 
MENSTRUAL 
St. PARITY COMPLAINTS DURATION DM HT OB HIV + OTHERS 
16382  38 1500‐2000  upto 10th  menstruating  P2L2  pain  0.25 months    +  + 
23862  48 500‐1000  upto 10 th  postmenopausal P3L3  pruritus  24 months   + 
19842  46 500‐1000  HSc  menstruating  P2L2  pain  10 months 
21382  40 1500‐2000  upto 10th   menstruating  P2L2  pruritus  6 months 
18676  46 1000‐1500  HSc  menstruating  P2L2  pruritus  6months       + + 
19962  52 500‐1000  upto 10th  postmenopausal P3L3  pruritus  12 months 
20143  37 500‐1000  HSc  menstruating  P2L2  pruritus  10 months 
20281  48 1000‐1500  HSc  postmenopausal P3L3  pain  0.25 months      + + 
23824  38 1500‐2000  HSc  menstruating  P2L2  discharge p/v  4 months   + 
15205  40 1000‐1500  upto 10 th  menstruating  P2L2  pruritus  12 months 
20695  47 >2000  graduate  menstruating  P3L3  pruritus  12 months 
28629  47 500‐1000  illiterate  postmenopausal nullipara  mass  36 months 
 
 
  
 
 IP/OP 
NO H/O STI SEX H/O SMOK TOB CLINICAL SIGNS INVESTIGATION HPE REPORT TREATMENT 
16382 mass blood sugar bartholin's cyst/abscess incision&drainage 
23862 discoloration biopsy lichen sclerosus simple vulvectomy 
19842 discoloration biopsy lichen sclerosus steroids 
21382 discoloration biopsy leucoplakia SSH steroids 
18676  + discoloration KOH mount vulvar candidiasis antifungals 
19962 discoloration biopsy lichen sclerosus steroids 
20143  + discoloration biopsy lichen sclerosus steroids 
20281 mass blood sugar bartholin's cyst/abscess incision&drainage 
23824 discoloration KOH mount vulvar candidiasis antifungals 
15205  + discoloration biopsy leucoplakia SSH steroids 
20695  + premarital discoloration biopsy leucoplakia SSH steroids 
28629  + extramarital  + ulcer biopsy 
poorly diff sq cell ca STAGE 
IV surgery+RT 
 
 
KEY TO MASTER CHART 
IP/OP NO   :  inpatient /outpatient number 
AGE    :  Age in years 
SES status   :  Socio-economic status (monthly income  
      in rupees) 
EDN status   :  Educational status 
HSc    :  Higher secondary schooling 
H/O STI   :  History of sexually transmitted infections 
HPE report   :  Histo-pathological report 
RT    :  Radiotherapy 
SSH    :  Simple squamous hyperplasia 
DM    :  Diabetes Mellitus 
HT    :  Hypertension 
OB    :  Obesity 
Sex H/O   :  Sexual History of Promiscuity 
SMOK   :  History of  Smoking 
TOB    :  Tobacco Abuse 
 
 
